Xiongjie Bi Selected Research

cucurbitacin IIb

1/2021

Cucurbitacin IIb improved active chromatin-induced systemic lupus erythematosus via balancing the percentage of Th17 and Treg cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Xiongjie Bi Research Topics

Disease

2	Neoplasms (Cancer) 01/2021 - 06/2019
2	Inflammation (Inflammations) 11/2019 - 01/2018
1	Hypertension (High Blood Pressure) 11/2023
1	Hepatocellular Carcinoma (Hepatoma) 06/2021
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2021
1	Fibrosis (Cirrhosis) 11/2019
1	Systemic Scleroderma (Systemic Sclerosis) 11/2019
1	Breast Neoplasms (Breast Cancer) 06/2019
1	Atherosclerotic Plaque (Atheroma) 01/2018
1	Atherosclerosis 01/2018

Drug/Important Bio-Agent (IBA)

2	Interferon Type IIBA 11/2023 - 11/2019
1	Biomarkers (Surrogate Marker)IBA 06/2021
1	GlypicansIBA 06/2021
1	Single-Domain AntibodiesIBA 01/2021
1	Immune Checkpoint InhibitorsIBA 01/2021
1	Immune Checkpoint ProteinsIBA 01/2021
1	AntibodiesIBA 01/2021
1	ChromatinIBA 01/2021
1	cucurbitacin IIbIBA 01/2021
1	Bleomycin (Blenoxane)FDA LinkGeneric 11/2019
1	Interferon Regulatory Factor-7 (Interferon Regulatory Factor 7)IBA 11/2019
1	Small Interfering RNA (siRNA)IBA 06/2019
1	Paclitaxel (Taxol)FDA LinkGeneric 06/2019
1	Liposomes (Liposome)IBA 06/2019
1	AGRO 100IBA 06/2019
1	CollagenIBA 01/2018
1	HomocysteineIBA 01/2018

Therapy/Procedure

2	Therapeutics 06/2019 - 01/2018
1	Immunotherapy 01/2021
1	Drug Therapy (Chemotherapy) 06/2019